By means of this letter I would like to invite you to become a member of a new Lancet Commission on Essential Medicines Policies. The goal of the Commission, which will be co-chaired by Prof Hans Hogerzeil of the University of Groningen (Netherlands), Prof Veronika Wirtz of the University of Boston (USA) and Dr Andy Gray of the University of Durban (South Africa), is to provide decision makers with lessons learned from 30 years essential medicines policies.
The Commission will be tasked to:
1. Synthesize lessons learned from the first 30 years of development and implementation of essential medicines policies
2. Develop an agenda for the next 20 years of institutional, regional, national and global policies on essential medicines
3. Raise global awareness of the relevance of essential medicine policies to achieve sustainable development goals, especially universal health coverage
4. Define the needs for further operational research that contributes to increasing the effectiveness and efficiency of essential medicines policies and programs
The Commission’s report will be published in The Lancet. The Commission will be free to express its academic views, based on its analysis of the most recent data. All Commissioners will be co-authors of the report. The report will help health decision-makers to see the medicine-related challenges they face across the various disease programs, to take better stock of the problems they face, develop solutions that are better adapted to their own health care systems, and anticipate the future evolution of global essential medicines policies.
Suggested input by Commissioners, proposed time-line
Commissioners are expected to attend a first brain-storming meeting in 2014. During this meeting the scope and outline of the report, the data available and the additional data needed will be identified. Then the work of data collection, data review, and drafting sections of the report will be divided between the Commissioners. A second meeting will be held on 9-11 March 2015, at which the data collected, draft analyses and provisional conclusions will be presented and recommendations will be formulated. Commissioners will then be requested to complete their contributions, to be collected and finalized by an editorial team, who will submit the report to The Lancet for external review. Interested Commissioners may later participate in an additional collaborative effort to prepare new teaching materials for undergraduate medical, pharmacy and public health students, on the basis of the report; or in possible follow-up activities.
Financial arrangements
Commissioners (or their universities or organizations) are expected to contribute their own time and travel costs. Modest travel funds are available for commissioners from low- and middle income countries. Additional funds are being sought to support the larger pieces of commissioned research or review work for the report.
Access to essential medicines is an essential contribution towards achieving universal access, and the report should therefore become part of the post-2015 health agenda. I hope you agree with me that it is a unique opportunity to prepare and present the scientific basis for essential medicine policies for the next decades; and hope that you are able and willing to make a contribution to this effort.
In case you would like to receive more information, please do not hesitate to contact one of the co-chairs at h.v.hogerzeil@umcg.nl or vwirtz@bu.edu or Graya1@ukzn.ac.za .
By means of this letter I would like to invite you to become a member of a new Lancet Commission on Essential Medicines Policies. The goal of the Commission, which will be co-chaired by Prof Hans Hogerzeil of the University of Groningen (Netherlands), Prof Veronika Wirtz of the University of Boston (USA) and Dr Andy Gray of the University of Durban (South Africa), is to provide decision makers with lessons learned from 30 years essential medicines policies.
The Commission will be tasked to:
1. Synthesize lessons learned from the first 30 years of development and implementation of essential medicines policies
2. Develop an agenda for the next 20 years of institutional, regional, national and global policies on essential medicines
3. Raise global awareness of the relevance of essential medicine policies to achieve sustainable development goals, especially universal health coverage
4. Define the needs for further operational research that contributes to increasing the effectiveness and efficiency of essential medicines policies and programs
The Commission’s report will be published in The Lancet. The Commission will be free to express its academic views, based on its analysis of the most recent data. All Commissioners will be co-authors of the report. The report will help health decision-makers to see the medicine-related challenges they face across the various disease programs, to take better stock of the problems they face, develop solutions that are better adapted to their own health care systems, and anticipate the future evolution of global essential medicines policies.
Suggested input by Commissioners, proposed time-line
Commissioners are expected to attend a first brain-storming meeting in 2014. During this meeting the scope and outline of the report, the data available and the additional data needed will be identified. Then the work of data collection, data review, and drafting sections of the report will be divided between the Commissioners. A second meeting will be held on 9-11 March 2015, at which the data collected, draft analyses and provisional conclusions will be presented and recommendations will be formulated. Commissioners will then be requested to complete their contributions, to be collected and finalized by an editorial team, who will submit the report to The Lancet for external review. Interested Commissioners may later participate in an additional collaborative effort to prepare new teaching materials for undergraduate medical, pharmacy and public health students, on the basis of the report; or in possible follow-up activities.
Financial arrangements
Commissioners (or their universities or organizations) are expected to contribute their own time and travel costs. Modest travel funds are available for commissioners from low- and middle income countries. Additional funds are being sought to support the larger pieces of commissioned research or review work for the report.
Access to essential medicines is an essential contribution towards achieving universal access, and the report should therefore become part of the post-2015 health agenda. I hope you agree with me that it is a unique opportunity to prepare and present the scientific basis for essential medicine policies for the next decades; and hope that you are able and willing to make a contribution to this effort.
In case you would like to receive more information, please do not hesitate to contact one of the co-chairs at h.v.hogerzeil@umcg.nl or vwirtz@bu.edu or Graya1@ukzn.ac.za .
การแปล กรุณารอสักครู่..
